Clinical resistance to imatinib: mechanisms and implications

被引：67

作者：

Hochhaus, A

Hughes, T

机构：

[1] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, D-68305 Mannheim, Germany

[2] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2004年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.hoc.2004.03.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within the kinase domain of BCR-ABL. Cytogenetic and molecular analyses at the time of resistance are suggested to guide therapy.

引用

收藏

页码：641 / +

页数：17

相关论文

共 51 条

[1] Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome [J].

Alimena, G ;

Breccia, M ;

Mancini, M ;

Ferranti, G ;

De Felice, L ;

Gallucci, C ;

Mandelli, F .

LEUKEMIA, 2004, 18 (02) :361-362

[2] Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8 [J].

Andersen, MK ;

Pedersen-Bjorgaard, J ;

Kjeldsen, L ;

Dufva, IH ;

Brondum-Nielsen, K .

LEUKEMIA, 2002, 16 (07) :1390-1393

[3] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].

Azam, M ;

Latek, RR ;

Daley, GQ .

CELL, 2003, 112 (06) :831-843

[4] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].

Bhatia, R ;

Holtz, M ;

Niu, N ;

Gray, R ;

Snyder, DS ;

Sawyers, CL ;

Arber, DA ;

Slovak, ML ;

Forman, SJ .

BLOOD, 2003, 101 (12) :4701-4707

[5] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[6] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[7] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority [J].

Bumm, T ;

Müller, C ;

Al-Ali, HK ;

Krohn, K ;

Shepherd, P ;

Schmidt, E ;

Leiblein, S ;

Franke, C ;

Hennig, E ;

Friedrich, T ;

Krahl, R ;

Niederwieser, D ;

Deininger, MWN .

BLOOD, 2003, 101 (05) :1941-1949

[8] Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib [J].

Corbin, AS ;

La Rosée, P ;

Stoffregen, EP ;

Druker, BJ ;

Deininger, MW .

BLOOD, 2003, 101 (11) :4611-4614

[9] Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α [J].

Cortes, J ;

Giles, F ;

O'Brien, S ;

Thomas, D ;

Garcia-Manero, G ;

Rios, MB ;

Faderi, S ;

Verstovsek, S ;

Ferrajoli, A ;

Freireich, EJ ;

Talpaz, M ;

Kantarjian, H .

BLOOD, 2003, 102 (01) :83-86

[10] Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy [J].

Cortes, JE ;

Talpaz, M ;

Giles, F ;

O'Brien, S ;

Rios, MB ;

Shan, J ;

Garcia-Manero, G ;

Faclerl, S ;

Thomas, DA ;

Wierda, W ;

Ferrajoli, A ;

Jeha, S ;

Kantarjian, HM .

BLOOD, 2003, 101 (10) :3794-3800

← 1 2 3 4 5 6 →